// App-Quantinova.ai

BSH19‐PO‐139 : Efficacy of eculizumab in paediatric patients with paroxysmal nocturnal haemoglobinuria in the International PNH Registry

Researchers

Presenter

  • . Urbano-Ispizua

Principal Investigators

  • T. Munir

  • A.G. Kulasekararaj

  • M. Bartels

  • C.J. Patriquin

  • B. Hoechsmann

  • A.A. Maschan

  • A. Wilson

  • P. Gustovic

  • H. Schrezenmeier

Medical Centers

  • Hospital Clinic Barcelona, Institute of Research Josep Carreras, Barcelona, Spain

  • Department of Haematological Medicine,King’s College Hospital, NIHR/Wellcome King’s Clinical Research Facility,London,United Kingdom

  • Department of Pediatric Immunology & Rheumatology, Wilhelmina Childrens Hospital, University Medical Center Utrecht, Utrecht, Netherlands

  • Division of General Surgery, University of Toronto, Toronto, ON, Canada

  • Institute of Transfusion Medicine, University of Ulm, Germany ,

  • Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Blood Service Baden-Wurttemberg, University Hospital Ulm, Ulm, Germany

  • Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

  • Alexion Pharmaceuticals, Inc., Boston, United States

  • Alexion Pharma GmbH, Zurich, Switzerland

Locations

  • Spain

  • United Kingdom

  • Netherlands

  • Canada

  • Germany

  • Russia

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT01374360

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved